News about Global Pharma

PTC Therapeutics Submits NDA for Vatiquinone to FDA

The vatiquinone NDA is based on data from the placebo-controlled MOVE-FA study as well as results from two long-term studies including pediatric and adult FA patients.

Global Pharma | 24/12/2024 | By Aishwarya |  375

OBI Pharma Partners with GlyTech to Promote GlycOBI Enabling Technologies Outreach in Japan

Under the terms of the Material Transfer Agreement, OBI will transfer some of its cutting-edge materials to GlyTech for research in advancing the efficient production of glycans for ADCs.

Global Pharma | 24/12/2024 | By Aishwarya |  531

Neuraxpharm and Pharmathen to Co-Develop Long-Acting Injectable Therapies

Under this agreement, Neuraxpharm will have exclusive rights to commercialise these therapies in Europe, and in countries outside of Europe where the group has a direct presence, while Pharmathen will have exclusive rights for North America and all other countries not covered by Neuraxpharm.

Global Pharma | 23/12/2024 | By Aishwarya |  523

Valneva Signs Agreement with Serum Institute of India for its Single Shot Chikungunya Vaccine

The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the framework of the USD 41.3 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union.

Global Pharma | 23/12/2024 | By Manvi |  679

HKBU's Aptamer for Rare Bone Disease Receives Orphan Drug and Rare Pediatric Disease Designations by FDA

The aptamer, originally developed to treat osteogenesis imperfecta, has been granted Orphan Drug Designation and Pediatric Rare Disease Designation by the US Food and Drug Administration (FDA).

Global Pharma | 23/12/2024 | By Manvi |  329

Photys Therapeutics and with Novo Nordisk to Develop Induced Proximity PHICS Technology

Under the terms of the agreement, Photys is eligible to receive up to USD 186 million in upfront, development and commercial milestone payments, in addition to R&D funding and tiered royalty payments on commercial sales.

Global Pharma | 23/12/2024 | By Aishwarya |  694

CuraTeQ Biologics Secures UK MHRA Approval for Bevqolva

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins.

Global Pharma | 23/12/2024 | By Aishwarya |  702

Verismo Therapeutics Completes Merger to Accelerate Clinical Development

The merger will accelerate the clinical development of SynKIR™-110 and SynKIR™-310 for solid tumor and blood cancer patients, respectively, solidifying Verismo's and HLB Group's collective mission to advance its innovative KIR-CAR platform for patients worldwide.

Global Pharma | 21/12/2024 | By Aishwarya |  783

Vanda Pharmaceuticals Receives Orphan Drug Designation Granted for VGT-1849A

VGT-1849A is a novel ASO treatment candidate for PV and other JAK2-driven hematologic malignancies.

Global Pharma | 21/12/2024 | By Aishwarya |  980

LSPedia to Expand Globally with New Office Launch in India in January 2025

The Hyderabad office will play a key role in LSPedia's global growth strategy, delivering exceptional service to customers in Bahrain, Bangladesh, Singapore, Switzerland, UK, and the balance of the EU.

Global Pharma | 21/12/2024 | By Aishwarya |  480